CL2020000467A1 - Anticuerpos multiespecíficos que se unen específicamente a los epítopos del virus del zika y usos de los mismos. - Google Patents

Anticuerpos multiespecíficos que se unen específicamente a los epítopos del virus del zika y usos de los mismos.

Info

Publication number
CL2020000467A1
CL2020000467A1 CL2020000467A CL2020000467A CL2020000467A1 CL 2020000467 A1 CL2020000467 A1 CL 2020000467A1 CL 2020000467 A CL2020000467 A CL 2020000467A CL 2020000467 A CL2020000467 A CL 2020000467A CL 2020000467 A1 CL2020000467 A1 CL 2020000467A1
Authority
CL
Chile
Prior art keywords
zika virus
bind specifically
multispecific antibodies
antibodies
virus epitopes
Prior art date
Application number
CL2020000467A
Other languages
English (en)
Inventor
Davide Corti
Original Assignee
Humabs Biomed Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Humabs Biomed Sa filed Critical Humabs Biomed Sa
Publication of CL2020000467A1 publication Critical patent/CL2020000467A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
    • G01N2333/185—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)

Abstract

LA INVENCIÓN SE REFIERE A ANTICUERPOS MULTIESPECÍFICOS, Y FRAGMENTOS DE UNIÓN A ANTÍGENO DE LOS MISMOS, QUE SE UNEN ESPECÍFICAMENTE A DISTINTOS EPÍTOPOS DEL VIRUS DEL ZIKA Y NEUTRALIZAN DE FORMA POTENTE LA INFECCIÓN POR EL ZIKV. LA INVENCIÓN TAMBIÉN SE REFIERE A ÁCIDOS NUCLEICOS QUE CODIFICAN TALES ANTICUERPOS Y FRAGMENTOS DE ANTICUERPOS. ADEMÁS, LA INVENCIÓN SE REFIERE AL USO DE LOS ANTICUERPOS Y FRAGMENTOS DE ANTICUERPOS DE LA INVENCIÓN EN LA PROFILAXIS Y EL TRATAMIENTO DE LA INFECCIÓN POR ZIKV.
CL2020000467A 2017-08-31 2020-02-26 Anticuerpos multiespecíficos que se unen específicamente a los epítopos del virus del zika y usos de los mismos. CL2020000467A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2017/071891 WO2019042555A1 (en) 2017-08-31 2017-08-31 MULTISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO ZIKA VIRUS EPITOPES AND USES THEREOF

Publications (1)

Publication Number Publication Date
CL2020000467A1 true CL2020000467A1 (es) 2020-06-19

Family

ID=59811299

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020000467A CL2020000467A1 (es) 2017-08-31 2020-02-26 Anticuerpos multiespecíficos que se unen específicamente a los epítopos del virus del zika y usos de los mismos.

Country Status (20)

Country Link
US (1) US11926658B2 (es)
EP (1) EP3676290A1 (es)
JP (2) JP7244489B2 (es)
KR (1) KR20200042499A (es)
CN (2) CN116693668A (es)
AU (1) AU2018322842A1 (es)
BR (1) BR112020000619A2 (es)
CA (1) CA3070780A1 (es)
CL (1) CL2020000467A1 (es)
CO (1) CO2020002060A2 (es)
CR (1) CR20200087A (es)
DO (1) DOP2020000043A (es)
EA (1) EA202090559A1 (es)
EC (1) ECSP20014362A (es)
IL (1) IL271515A (es)
MX (1) MX2020002181A (es)
MY (1) MY201774A (es)
PH (1) PH12020550025A1 (es)
SG (1) SG11202000206SA (es)
WO (2) WO2019042555A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111615397A (zh) 2017-11-03 2020-09-01 武田疫苗股份有限公司 寨卡疫苗和免疫原性组合物及其使用方法
MX2020005554A (es) 2017-11-30 2020-10-12 Takeda Vaccines Inc Vacunas y composiciones inmunogenas para zika y metodos para usarlas.
KR102365464B1 (ko) * 2019-12-24 2022-02-22 강원대학교산학협력단 지카바이러스 재조합 서브유닛 백신의 개발 및 이의 제조방법
US20230324404A1 (en) * 2020-05-20 2023-10-12 Takeda Vaccines, Inc. Method for detection of zika virus specific antibodies
WO2021236225A1 (en) * 2020-05-20 2021-11-25 Takeda Vaccines, Inc. Method for detection of zika virus specific antibodies
WO2022001803A1 (zh) * 2020-06-28 2022-01-06 神州细胞工程有限公司 一种降低病毒ade效应的方法
WO2022109443A1 (en) * 2020-11-23 2022-05-27 The Regents Of The University Of Michigan Single-chain antibody against flavivirus ns1 protein
CN114958747A (zh) * 2022-06-08 2022-08-30 中国科学院动物研究所 一种多能干细胞诱导产生兴奋性和抑制性神经元的方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3766162A (en) 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
AU2004252170B2 (en) 2003-06-27 2011-01-27 Biogen Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
MX2009012343A (es) 2007-05-14 2010-02-10 Biogen Idec Inc Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello.
WO2015103072A1 (en) * 2013-12-30 2015-07-09 Epimab Biotherapeutics Fabs-in-tandem immunoglobulin and uses thereof
EP2980099A1 (en) * 2014-07-31 2016-02-03 Bernhard-Nocht-Institut für Tropenmedizin Compositions and methods for detecting flaviviridae infections
CA2992531C (en) 2015-07-16 2023-09-26 Bharat Biotech International Limited Vaccine compositions
AU2017230112A1 (en) 2016-03-11 2018-10-04 The Johns Hopkins University Live attenuated Zika virus vaccine
CN105954512A (zh) 2016-06-01 2016-09-21 卢氏实验室公司 一种快速免疫层析法检测塞卡病毒Zika virus的检测条
WO2018010789A1 (en) 2016-07-13 2018-01-18 Humabs Biomed Sa Novel antibodies specifically binding to zika virus epitopes and uses thereof
TW201815821A (zh) 2016-07-18 2018-05-01 美商再生元醫藥公司 抗茲卡病毒抗體及使用方法
CN110172095B (zh) 2016-08-10 2020-09-04 中国科学院微生物研究所 一种高中和活性的寨卡病毒人源单克隆抗体及其应用
WO2018081754A1 (en) * 2016-10-29 2018-05-03 University Of Miami Anti-zika virus antibodies
US11021533B2 (en) * 2016-11-02 2021-06-01 Vanderbilt University Human Zika virus antibodies and methods of use therefor
CN106841601A (zh) 2016-12-30 2017-06-13 广州市达瑞生物技术股份有限公司 寨卡病毒多片段融合蛋白的制备及IgG/IgM抗体检测试剂盒
CN106885903B (zh) 2017-03-08 2018-12-28 中国人民解放军军事医学科学院基础医学研究所 一种寨卡病毒e抗原及其在检测抗寨卡病毒抗体中的应用

Also Published As

Publication number Publication date
EP3676290A1 (en) 2020-07-08
EA202090559A1 (ru) 2020-06-17
MX2020002181A (es) 2020-07-20
CA3070780A1 (en) 2019-03-07
CO2020002060A2 (es) 2020-06-09
US11926658B2 (en) 2024-03-12
PH12020550025A1 (en) 2021-02-15
AU2018322842A1 (en) 2020-01-16
SG11202000206SA (en) 2020-03-30
IL271515A (en) 2020-02-27
CN111344302B (zh) 2023-03-10
CN116693668A (zh) 2023-09-05
JP2023071956A (ja) 2023-05-23
WO2019042555A1 (en) 2019-03-07
JP7244489B2 (ja) 2023-03-22
JP2020531000A (ja) 2020-11-05
CR20200087A (es) 2020-08-07
DOP2020000043A (es) 2020-09-15
US20200317755A1 (en) 2020-10-08
WO2019043166A1 (en) 2019-03-07
CN111344302A (zh) 2020-06-26
MY201774A (en) 2024-03-16
KR20200042499A (ko) 2020-04-23
BR112020000619A2 (pt) 2020-07-14
ECSP20014362A (es) 2020-04-22

Similar Documents

Publication Publication Date Title
CL2020000467A1 (es) Anticuerpos multiespecíficos que se unen específicamente a los epítopos del virus del zika y usos de los mismos.
DOP2021000026A (es) Anticuerpos que se unen específicamente a los epítopos del virus del zika y usos de los mismos
CL2018000502A1 (es) Anticuerpos biespecíficos para pd1 y tim3 útiles como inmunomoduladores o en el tratamiento del cáncer.
CL2020000919A1 (es) Anticuerpos específicos cd47/pd-l1.
CY1124252T1 (el) Anti-lag3 αντισωματα και θραυσματα συνδεσης αντιγονου
CO2018010458A2 (es) Composiciones y anticuerpos anti-tim-3
CY1121893T1 (el) Μορια αντισωματος κατα της τιμ-3 και χρησεις αυτων
CL2017001154A1 (es) Moléculas de unión específicas para cd73 y usos de las mismas
EA201791485A1 (ru) Анти-cd47-антитела и их применения
MY187161A (en) Antibodies that potently neutralize hepatitis b virus and uses thereof
EA201692504A1 (ru) Триспецифичные связывающие молекулы и способы их применения
PE20190737A1 (es) Anticuerpos anti-cd27
BR112017025191A2 (pt) anticorpos contra ox40 e uso dos mesmos
PH12021550521A1 (en) Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof
EA201792220A1 (ru) Опосредуемая антителом нейтрализация вируса чикунгунья
CO2018012497A2 (es) Anticuerpos de interferón beta y usos de los mismos
CO2017010631A2 (es) Método para purificación de proteína
GT201800034A (es) Anticuerpos anti-cd154 y métodos de uso de estos
UY36820A (es) Anticuerpos monoclonales específicos para el antígeno p del virus respiratorio sincicial humano (vrsh), producidos y secretados por hibridomas celulares, útiles para la detección y el diagnóstico de la infección causada por vrsh
CO2017004753A2 (es) Anticuerpos que se unen a ccr6
AR109683A1 (es) Anticuerpos contra el factor xi y sus usos
UY37449A (es) Anticuerpos anti-chikv y usos de éstos
EA202090580A2 (ru) Триспецифичные связывающие молекулы и способы их применения